Revolution Medicines shared early-stage data supporting a planned Phase 3 trial in pancreatic cancer that combines two KRAS-targeting drugs. The company said it will evaluate the combination after the data set helped guide the move into Phase 3. Revolution framed the strategy around addressing KRAS-driven disease biology that limits single-agent approaches, particularly where resistance emerges over time. The first look on the road to Phase 3 gives the market an early read-through of how Revolution expects the combination to perform in a more definitive development stage. For biotech investors, the announcement highlights how KRAS programs increasingly rely on combinatorial regimens rather than first-generation single-molecule sequencing.